GenomeScan is partnering with Olink Proteomics to bring proteomics to the next level by enabling high-throughput analysis of thousands of proteins, while using less than a drop of blood.
Olink’s PEA technology that is based on dual antibody recognition results in the coupling of DNA oligonucleotides and boasts exceptional levels of specificity, sensitivity and dynamic range.
By combining different omics approaches, GenomeScan helps facilitates researchers in identifying the regulators of biological processes, identifying new targets for drug discovery, evaluating therapeutic interventions, and identifying biomarkers that can be used for diagnosis, prognosis, and disease monitoring, leading to more precise and effective treatments.
7 March 2025 to 8 March 2026 'Unseen' reveals how, for centuries, medical science has taken the male body as the norm, often overlooking women and gender-diverse individuals....
Leiden researchers have made a groundbreaking discovery in understanding type 1 diabetes (T1D). Led by Professor Bart Roep, LUMC researchers have identified how genetic...
Last night, Leiden Bio Science Park looked a little different. With colored lights in hand, we set out to illuminate the park—bringing visibility to the 300 million people...